At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 48 target
Drug / intervention
ZG005 Powder for Injection +4 moredrug
Likely dose
ZG005 Powder for Injection 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06241235Phase 2RecruitingMonitorUpdated 26mo ago · Completion was 2mo agoSlow Enrollment
Monitor
A Phase I/II Study to Evaluate Safety and Pharmacokinetics and Initial Efficacy of ZG005 in Combination With Paclitaxel Plus Cisplatin/Carboplatin ± Bevacizumab in Patients With Advanced Cervical Carcinoma
In Brief
A Phase 2 clinical trial evaluating ZG005 Powder for Injection, Paclitaxel, and 3 other interventions for Cervical Carcinoma. Currently recruiting, targeting 48 participants across 1 site.
Signals
Enrolling slower than its timeline implies
Detailed Summary
This is a multicenter, open-label phase I/II study for the first-line treatment of advanced cervical cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Carcinoma
CountriesChina
Collaborators--
Timeline
Phase 2RecruitingOverdue
202420252026
First PostedFeb 2024
Enrollment StartMar 2024
Primary CompletionMay 2026
TodayJul 2026
First PostedFeb 5, 2024
Enrollment StartMar 27, 2024
Primary CompletionMay 1, 2026
TodayJul 1, 2026
Enrollment to primary: 2.1 yearsPosted 2.4 years ago
Interventions
ZG005 Powder for Injectiondrug
ZG005 for dose escalations are set as 10 mg/kg, 15 mg/kg and other doses after discussion, intravenous infusion(IV), once every 3 weeks (Q3W). ZG005 for dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.
Paclitaxeldrug
IV infusion
Bevacizumabbiological
IV infusion
Cisplatindrug
IV infusion
Carboplatindrug
IV infusion